PSMA & Beyond Conference
@PSMAconference
Followers
359
Following
263
Media
47
Statuses
169
Conference focused on theranostics. 2026 conference will be held in Los Angeles on March 26-27. Co-sponsored by UCLA/UCSF/PCF.
Los Angeles
Joined May 2023
New in @ASCO DailyNews PSMA-PET for Therapy Response in Prostate Cancer Quantitative, whole-body imaging is here, but challenges remain: standardization, AI, & adoption. 🧠Insights from @CalaisJeremie, @UCLA 🔗 https://t.co/aWXCJcNels
#Theranostics #NuclearMedicine @UCLAHealth
dailynews.ascopubs.org
PSMA PET is now routinely used for staging and restaging, offering earlier and more sensitive lesion detection, whole-body evaluation, and access to quantitative metrics. To fully harness the...
0
4
11
The Costs to Our Patients | Journal of Nuclear Medicine
jnm.snmjournals.org
I am a cancer survivor, 2 different kinds—prostate cancer and metastatic melanoma. The reason I am a survivor is that I received patient-individualized therapies , administered by an excellent staff...
1
5
12
The origins and evelution of #PSMA! @radnucmp @UTSWMedCenter retraces PSMA's journey—from LNCaP & cDNA cloning to the breakthrough that NAALADase is PSMA. His work with Alan Kozikowski paved the way for PSMA-11 & PSMA-617, transforming care for #mCRPC patients. #WatchNow on
0
1
7
Pre-chemo 177Lu-PSMA Trials: #PSMAfore, #SPLASH, and #ECLIPSE. Presentation by @EAntonarakis @UMNCancer comparing PSMA radioligand therapy trials in #mCRPC for the post-ARPI, pre-chemotherapy setting. #WatchNow on UroToday > https://t.co/8LhwqdWZac
@PCFnews @PSMAconference
0
9
21
Sequencing with RLT in #mCRPC. Presentation by @TDorffOnc @cityofhope addressing treatment sequencing in advanced #ProstateCancer. She notes PARP inhibitors show superior efficacy when used early in BRCA2-altered patients. #WatchNow > https://t.co/CYc3gBt9uT
@PSMAconference
1
2
5
Radiation safety and ecology: Comparison of Practices in the US and the World. 🚨 Radiation safety in theranostics isn't one-size-fits-all. , Catherine Meyer breaks down key infrastructure needs: 🛡️ Shielding (structural + operational) 🏥 Patient release (Germany vs. US/Aus) ♻️
0
1
3
What's the role of Primary Score in #ProstateCancer diagnosis? @DrMHofman @PeterMacCC shares insights at #PSMAandBeyond2025! Watch to learn more about this innovative tool > https://t.co/Bug0TmsbHx
@PSMAconference @PCFnews @UCLA @UCSF
0
4
18
Overview of Clinical Trials of PSMA RPT in 2025. @CalaisJeremie reviews the evolving landscape of #PSMA therapy trials across all stages of #ProstateCancer. From pre-chemo to hormone-sensitive disease, highlights include: ✅ Imaging-guided dosing ✅ Alpha emitters ✅ “Cocktail”
0
6
13
AI applications for simplifying radiopharmaceutical dosimetry workflows. @IreneBuvat @LitoCurie discusses how #AI can simplify personalized dosimetry in radiopharmaceutical therapy, addressing the "catch-22" where complexity limits clinical use and evidence collection. #WatchNow
0
2
3
Incorporating PSMA PET into clinical trials. Michael Morris, MD @MSKCancerCenter discusses radioligand therapy strategies for polymetastatic castration-sensitive prostate cancer. He highlights longer survival timelines affecting toxicity-benefit considerations. #WatchNow >
0
4
6
Reimagining PSMA radioligand therapy for castration-sensitive #ProstateCancer. Presentation by Michael Morris, MD @MSKCancerCenter discussing the implementation of radioligand therapy in polymetastatic castration-sensitive prostate cancer. #WatchNow > https://t.co/yaufWQRRPK
1
3
9
Beyond the 23 Gy Threshold: Renal Toxicity, EBRT, and RLT. Presentation by Ana Ponce Kiess questioning the 23 Gy kidney threshold in radiopharma therapy—tracing its roots to 1940s EBRT data. She calls for new NTCP models tailored to PSMA RLT and highlights the FDA’s evolving
0
1
2
Outstanding PSMA imaging biomarker data from ENZA-P trial @drlouiseemmett @DrMHofman @CalaisJeremie #ASCO25
1
2
6
Beachside GU Cast with @DrMHofman @RenuEapen @declangmurphy to hear Michael’s #ASCO25 PSMA theranostic highlights. Plus some CAIX renal excitement
1
6
18
Plan ahead! The next PSMA conference will be held March 26-27th, 2026. This is the go to conference for learning about clinical use of PSMA radioligand therapies and discussing future directions. It will again be held at the Luskin Center at UCLA.
2
8
29
Do dosimetric behaviors and dose–effect relationships in ¹⁷⁷Lu-DOTATATE PRRT warrant consideration of alternative treatment strategies rather than the current fixed-activity protocol? https://t.co/7X5J0e8Zab
#NuclearMedicine #Dosimetry #RPTherapy @gunjankayal
0
9
19
📢 #ASCO25 | 3:00 PM–4:30 PM Clinical Science Symposium | Radioligand Therapy Remix: Finding the Right Patient for the Perfect Track | Jeremie Calais, MD, PhD dissects BULLSEYE (^177Lu‑PSMA���617 in oHSPC), VIOLET (^161Tb‑PSMA‑I&T in mCRPC), and ENZA‑p (PSMA‑PET TTVol &
0
15
33
Radioligand therapy remix: Finding the right patient for the perfect track. Presentation by @CalaisJeremie @UCLA. #ASCO25 written coverage by @chavarriagaj @UofT > https://t.co/vwYKOB9CeF
@ASCO
0
20
51
The UCLA Nuclear Medicine team is on the ground at #ASCO25 ! Every year, nuclear medicine & theranostics shine brighter on the #ASCO stage. @UCLA @UCLATheranostic @UCLAJCCC
#CancerResearch #NuclearMedicine #Theranostics
0
4
29